P. Abram

Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.

D. Rea, G. Steger, N. Maass, 2005, Cancer treatment reviews.

HER2-positive early breast cancers: What proportion are receiving adjuvant trastuzumab therapy? A multicenter audit.

D. Dodwell, C. Palmieri, O. Gojis, 2010 .

Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group.

S. Cawthorn, M. Kissin, I. Smith, 1996, Journal of the National Cancer Institute.

Optimising antiemesis in cancer chemotherapy.

J. Dundee, R. Ghaly, G. Lynch, 1987, British medical journal.

Medical Research Council (MRC) randomised trial of adjuvant chemotherapy in high grade glioma (HGG)- BR05.

P. Lantos, N. Bleehen, F. Senanayake, 1998 .

Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer

I. Monypenny, J. Gattuso, R. Carpenter, 2009, Breast Cancer Research and Treatment.

Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.

I Vergote, I. Vergote, P Abram, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical development of fulvestrant ("Faslodex").

Anthony Howell, A. Howell, Paul Abram, 2005, Cancer treatment reviews.

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.

Anthony Howell, A. Howell, J. Robertson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

94 A multicentre audit of HER2 positive Early Breast Cancers and the reasons why patients do not receive trastuzumab therapy

D. Dodwell, S. Tovey, C. Palmieri, 2010 .